Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07575269 · ClinicalTrials.gov registry record · NA
Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
A NA study, sponsored by Boston Scientific Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 571
- Enrollment target
NCT07575269 is a NA study that is actively recruiting participants, run by Boston Scientific Corporation. The registered enrollment target is 571 participants.
The verdict
NCT07575269, a NA study, is actively recruiting participants, sponsored by Boston Scientific Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 571 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if the FARAFLEX™ Mapping and pulsed field ablation (PFA) System can safely and effectively treat symptomatic, drug-refractory Paroxysmal atrial fibrillation (PAF) and Persistent atrial fibrillation (PersAF). The main question it aims to answer is: Is the FARAFLEX Mapping and PFA System a safe and effective treatment for patients? Participants will undergo an ablation procedure using the FARAFLEX Mapping and PFA System.
Interventions
- DEVICE FARAFLEX Mapping and Pulsed Field Ablation (PFA) System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2026-06-12 |
| Est. Completion | 2030-01-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07575269
The ClinicalTrials.gov registry entry for NCT07575269 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 571 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FARAFLEX Mapping and Pulsed Field Ablation (PFA) System is the first listed.
NCT07575269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07575269 about?
NCT07575269 is a clinical study titled "Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation". The goal of this clinical trial is to learn if the FARAFLEX™ Mapping and pulsed field ablation (PFA) System can safely and effectively treat symptomatic, drug-refractory Paroxysmal atrial fibrillation (PAF) and Persistent atrial fibrillation (PersAF). The main question it aims to answer is: Is the ...
What is the current status of trial NCT07575269?
This trial is currently recruiting. It is a NA study. The enrollment target is 571 participants. The study started on 2026-06-12. Estimated completion is 2030-01-01.
What interventions are being tested in trial NCT07575269?
The interventions under investigation include: FARAFLEX Mapping and Pulsed Field Ablation (PFA) System (DEVICE).
Who is sponsoring clinical trial NCT07575269?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.